📊 SNOA Key Takeaways
Is Sonoma Pharmaceuticals, Inc. (SNOA) a Good Investment?
Sonoma Pharmaceuticals faces significant operational headwinds with flat revenue growth (0% YoY) and substantial net losses of $3.2M. Despite improving loss trends YoY, the company is burning $4.1M in free cash flow annually with only $2.4M in cash reserves, creating a critical cash runway concern within 6-9 months absent capital raises or operational improvements.
Sonoma Pharmaceuticals, Inc. Key Strengths (SNOA)
- Improving profitability trajectory - net loss narrowing 8.2% YoY and EPS improving 32.3% YoY indicates operational traction
- Healthy gross margin of 38% demonstrates product economics are sound if scale can be achieved
- Strong liquidity position with 2.50x current ratio and 1.75x quick ratio, plus minimal debt burden
SNOA Stock Risks: Sonoma Pharmaceuticals, Inc. Investment Risks
- Stagnant revenue growth at 0% YoY threatens long-term viability and suggests market adoption challenges
- Negative free cash flow of $4.1M annually with only $2.4M cash reserves creates acute liquidity risk within 6-9 months
- Operating losses of $2.5M indicate inability to achieve profitability at current revenue levels; requires either 30%+ revenue growth or significant cost reduction
- Zero insider buying activity in past 90 days may signal lack of confidence from management
Key Metrics to Watch
- Quarterly revenue growth - must return to positive territory to validate turnaround
- Operating cash flow trend - critical to extend cash runway and demonstrate path to breakeven
- Cash balance and burn rate - watch for announcements of capital raises or financing activities
- Gross margin sustainability - ensure product mix and pricing remain stable during scaling
Sonoma Pharmaceuticals, Inc. (SNOA) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 2.50x current ratio provides a solid financial cushion.
SNOA Profit Margin, ROE & Profitability Analysis
SNOA vs Healthcare Sector: How Sonoma Pharmaceuticals, Inc. Compares
How Sonoma Pharmaceuticals, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Sonoma Pharmaceuticals, Inc. Stock Overvalued? SNOA Valuation Analysis 2026
Based on fundamental analysis, Sonoma Pharmaceuticals, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Sonoma Pharmaceuticals, Inc. Balance Sheet: SNOA Debt, Cash & Liquidity
SNOA Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Sonoma Pharmaceuticals, Inc.'s revenue has shown modest growth of 5% over the 5-year period. The most recent EPS of $-2.79 indicates the company is currently unprofitable.
SNOA Revenue Growth, EPS Growth & YoY Performance
SNOA Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2026 | $3.6M | -$534.0K | $-0.48 |
| Q2 2026 | $3.6M | -$534.0K | $-0.32 |
| Q1 2026 | $3.4M | -$1.1M | $-0.76 |
| Q3 2025 | $3.1M | -$610.0K | $-0.63 |
| Q2 2025 | $2.7M | -$610.0K | $-0.59 |
| Q1 2025 | $3.4M | -$1.1M | $-0.07 |
| Q3 2024 | $2.9M | -$866.0K | $-0.08 |
| Q2 2024 | $2.7M | -$887.0K | $-0.29 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Sonoma Pharmaceuticals, Inc. Dividends, Buybacks & Capital Allocation
SNOA SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Sonoma Pharmaceuticals, Inc. (CIK: 0001367083)
📋 Recent SEC Filings
❓ Frequently Asked Questions about SNOA
What is the AI rating for SNOA?
Sonoma Pharmaceuticals, Inc. (SNOA) has an AI grade of C with 75% confidence, based on fundamental analysis of SEC EDGAR filings.
What are SNOA's key strengths?
Claude: Improving profitability trajectory - net loss narrowing 8.2% YoY and EPS improving 32.3% YoY indicates operational traction. Healthy gross margin of 38% demonstrates product economics are sound if scale can be achieved.
What are the risks of investing in SNOA?
Claude: Stagnant revenue growth at 0% YoY threatens long-term viability and suggests market adoption challenges. Negative free cash flow of $4.1M annually with only $2.4M cash reserves creates acute liquidity risk within 6-9 months.
What is SNOA's revenue and growth?
Sonoma Pharmaceuticals, Inc. reported revenue of $19.5M.
Does SNOA pay dividends?
Sonoma Pharmaceuticals, Inc. does not currently pay dividends.
Where can I find SNOA SEC filings?
Official SEC filings for Sonoma Pharmaceuticals, Inc. (CIK: 0001367083) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is SNOA's EPS?
Sonoma Pharmaceuticals, Inc. has a diluted EPS of $-1.89.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is SNOA's fundamental grade?
Based on our AI fundamental analysis in June 2026, Sonoma Pharmaceuticals, Inc. has a C grade with 75% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is SNOA stock overvalued or undervalued?
Valuation metrics for SNOA: ROE of -102.6% (sector avg: 15%), net margin of -16.3% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is SNOA's AI grade for 2026?
Our dual AI analysis gives Sonoma Pharmaceuticals, Inc. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is SNOA's free cash flow?
Sonoma Pharmaceuticals, Inc.'s operating cash flow is $-3.9M, with capital expenditures of $192.0K. FCF margin is -21.1%.
How does SNOA compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -16.3% (avg: 12%), ROE -102.6% (avg: 15%), current ratio 2.50 (avg: 2).